Arabic Arabic English English French French German German
dark

Spago Nanomedicals Phase 1 Study with SpagoPix Shows Clear Contrast Enhancement and is Expanded into New Indications

Spago Nanomedical AB announced that interim results from the second dose group in the company’s ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix is well tolerated and provides clear contrast enhancement in MRI images of solid tumors in the breast, as well as in the pancreas and liver. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

Next Post

BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

Related Posts
Total
0
Share